Previous 10 | Next 10 |
2024-03-17 19:46:57 ET More on the markets SPTM: A Solid But Unnecessary Total Market ETF S&P 500: Time To Hedge, Here's How How the Magnificent 7 valuations stack up against bubbles of yore S&P 500 notches two-week losing streak ahead of key Fed rate...
2024-03-10 13:08:00 ET More on ALX Oncology, Bicycle Therapeutics, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation ...
2024-03-08 08:15:00 ET Could this be the year biotech stocks bounce back? The industry has been in a slump over the past couple of years, but it started 2024 with a bang. The SPDR S&P Biotech ETF , which tracks an industry index, is up by nearly 13% year to date. Still, it's too...
2024-03-01 18:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-19 08:00:00 ET What is a reasonable sum of money to start investing in stocks? $10,000? $1,000? $500? The truth is, thanks to online brokers who now offer trades at low or no fees and fractional shares, investors can get their skin in the game at almost any price. However, for t...
PALM BEACH, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Recent reports project that the anal cancer market will continue its recent growth through 2030. An article on the MD Anderson website. It said: “More than 8,000 people in the U.S. are diag...
2024-02-06 22:13:03 ET Exelixis, Inc. (EXEL) Q4 2023 Earnings Conference Call February 06, 2024, 05:00 PM ET Company Participants Susan Hubbard - EVP, Public Affairs and IR Mike Morrissey - President and CEO Chris Senner - CFO PJ Haley - EVP, Commercial D...
2024-02-06 20:45:15 ET Image source: The Motley Fool. Exelixis (NASDAQ: EXEL) Q4 2023 Earnings Call Feb 06, 2024 , 5:00 p.m. ET Operator Continue reading For further details see: Exelixis (EXEL) Q4 2023 Earnings Call Transcript
2024-02-06 16:11:08 ET More on Exelixis Exelixis: 2024 Looking Good In The Mid-Term Exelixis: Bullish Despite The High Stakes Game Of Cabometyx Patent Battles Exelixis Q4 2023 Earnings Preview Exelixis forecasts 2024 revenue between $1.83B - $1.93B Se...
- Total Revenues of $480 million for the Fourth Quarter of 2023, $1,830 million for the Fiscal Year 2023 - - Cabozantinib Franchise Achieved $1,629 million in U.S. Net Product Revenues for the Fiscal Year 2023, including $429 million for the Fourth Quarter of 2023 - ...
News, Short Squeeze, Breakout and More Instantly...
- Presentations to be webcast on www.exelixis.com - Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in May: BofA Securities 2024 Health Care Conf...
2024-05-02 10:47:03 ET DoorDash Inc (DASH) DASH is trading DOWN for the last 4 days, and it at trading at $109.70 with volume of 8,405,700 and a one day change of $-17.76 (-13.92%). DoorDash Inc has a 52-week low of 60.36 and a 52-week high of $143.34. The business's 50-day moving a...
2024-05-01 02:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...